TG Therapeutics, Inc.
LSE: 0VGI.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Michael S. Weiss
- Employees
- 352
- Headquarters
- Morrisville, United States
- IPO year
- 2018
- Market cap
- $5.3B
- Website
- https://www.tgtherapeutics.com
Loading 0VGI…
Loading profile data…Frequently asked questions about 0VGI
What does TG Therapeutics, Inc. (0VGI.L) do?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
Where does 0VGI.L trade?
TG Therapeutics, Inc. (0VGI.L) trades on the London Stock Exchange.
What sector is 0VGI.L in?
TG Therapeutics, Inc. (0VGI.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of TG Therapeutics, Inc.?
Michael S. Weiss is the chief executive officer of TG Therapeutics, Inc. (0VGI.L).
Where is TG Therapeutics, Inc. headquartered?
TG Therapeutics, Inc. is headquartered in United States.
Does 0VGI.L pay a dividend?
TG Therapeutics, Inc. (0VGI.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0VGI.L go public?
TG Therapeutics, Inc. (0VGI.L) completed its initial public offering in 2018.